Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System
Supramolecular mesoporous silica nanoparticles (MSNs) offer distinct properties as opposed to micron-sized silica particles in terms of their crystal structure, morphology–porosity, toxicity, biological effects, and others. MSN biocompatibility has touched the pharmaceutical realm to exploit its rob...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.886981/full |
| _version_ | 1828324982447407104 |
|---|---|
| author | Farahidah Mohamed May K. Oo Bappaditya Chatterjee Batoul Alallam |
| author_facet | Farahidah Mohamed May K. Oo Bappaditya Chatterjee Batoul Alallam |
| author_sort | Farahidah Mohamed |
| collection | DOAJ |
| description | Supramolecular mesoporous silica nanoparticles (MSNs) offer distinct properties as opposed to micron-sized silica particles in terms of their crystal structure, morphology–porosity, toxicity, biological effects, and others. MSN biocompatibility has touched the pharmaceutical realm to exploit its robust synthesis pathway for delivery of various therapeutic molecules including macromolecules and small-molecule drugs. This article provides a brief review of MSN history followed by special emphasis on the influencing factors affecting morphology–porosity characteristics. Its applications as the next-generation drug delivery system (NGDDS) particularly in a controlled release dosage form via an oral drug delivery system are also presented and shall be highlighted as oral delivery is the most convenient route of drug administration with the economical cost of development through to scale-up for clinical trials and market launch. |
| first_indexed | 2024-04-13T19:14:25Z |
| format | Article |
| id | doaj.art-3a8ed81a2f434e51b33941c78ed1d920 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T19:14:25Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3a8ed81a2f434e51b33941c78ed1d9202022-12-22T02:33:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-06-011310.3389/fphar.2022.886981886981Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery SystemFarahidah Mohamed0May K. Oo1Bappaditya Chatterjee2Batoul Alallam3Pharmaceutical Technology Department, Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, MalaysiaPharmaceutical Technology Department, Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, MalaysiaShobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’s Narsee Monjee Institute of Management Studies, Mumbai, IndiaCluster of Integrative Medicine, Advanced Medical and Dental Institute, University of Science Malaysia, Penang, MalaysiaSupramolecular mesoporous silica nanoparticles (MSNs) offer distinct properties as opposed to micron-sized silica particles in terms of their crystal structure, morphology–porosity, toxicity, biological effects, and others. MSN biocompatibility has touched the pharmaceutical realm to exploit its robust synthesis pathway for delivery of various therapeutic molecules including macromolecules and small-molecule drugs. This article provides a brief review of MSN history followed by special emphasis on the influencing factors affecting morphology–porosity characteristics. Its applications as the next-generation drug delivery system (NGDDS) particularly in a controlled release dosage form via an oral drug delivery system are also presented and shall be highlighted as oral delivery is the most convenient route of drug administration with the economical cost of development through to scale-up for clinical trials and market launch.https://www.frontiersin.org/articles/10.3389/fphar.2022.886981/fullmesoporoussilicananoparticlesinsulinpharmaceuticaloral |
| spellingShingle | Farahidah Mohamed May K. Oo Bappaditya Chatterjee Batoul Alallam Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System Frontiers in Pharmacology mesoporous silica nanoparticles insulin pharmaceutical oral |
| title | Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System |
| title_full | Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System |
| title_fullStr | Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System |
| title_full_unstemmed | Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System |
| title_short | Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System |
| title_sort | biocompatible supramolecular mesoporous silica nanoparticles as the next generation drug delivery system |
| topic | mesoporous silica nanoparticles insulin pharmaceutical oral |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.886981/full |
| work_keys_str_mv | AT farahidahmohamed biocompatiblesupramolecularmesoporoussilicananoparticlesasthenextgenerationdrugdeliverysystem AT maykoo biocompatiblesupramolecularmesoporoussilicananoparticlesasthenextgenerationdrugdeliverysystem AT bappadityachatterjee biocompatiblesupramolecularmesoporoussilicananoparticlesasthenextgenerationdrugdeliverysystem AT batoulalallam biocompatiblesupramolecularmesoporoussilicananoparticlesasthenextgenerationdrugdeliverysystem |